Hematologic Oncology

Michael L. Grossbard, MD, discusses the phase III DYNAMO study examining the use of duvelisib in the treatment of patients with indolent non-Hodgkin lymphoma.

The benefit of single-agent acalabrutinib continued well over 3 years after treatment initiation in patients with relapsed/refractory chronic lymphocytic leukemia.

Alvin H. Schmaier, MD, discusses the primary and secondary management of cancer-related thrombosis.

Joshua Brody, MD, discusses the utility of in-situ vaccines as a novel way to harness immune response and extend the reach of immunotherapy in patients with advanced-stage indolent non-Hodgkin lymphoma.

Corey S. Cutler, MD, MPH, FRCPC, discusses some of the novel preventive strategies against graft-versus-host disease.

Syed Rizvi, MD, discusses research efforts exploring brentuximab vedotin combinations in patients with Hodgkin lymphoma.

Brad S. Kahl, MD, outlines the available treatment options in indolent non-Hodgkin lymphoma, factors that may influence treatment selection, and promising agents on the horizon.

Brad Kahl, MD, discusses the efficacy of targeted agents across indolent lymphomas.

Aaron Goodman, MD, discusses the need for molecular subtyping in T-cell lymphomas.

Mohammad Maher Abdul-Hay, MD, discusses the future of targeted therapy in acute lymphoblastic leukemia.

Tania Jain, MBBS, discusses the potential for graft-versus-host disease as a complication of allogeneic stem cell transplant.

Alvin H. Schmaier, MD, discusses the secondary management of thrombosis in patients with hematologic malignancies.

Ruben Mesa, MD, and his patient Antje Hjerpe, who has been living with essential thrombocythemia for 35 years, share the challenges in diagnosing ET, the current state of treatment and ongoing research efforts, and resources Mesa recommends on educating both physicians and patients on myeloproliferative neoplasms and components of care.

This week we have collaborated with NYU Langone Health to highlight important topics facing oncologists today. Join us on Saturday, May 9, 2020 at 11 AM EDT.

Prapti Patel, MD, discusses data from the MEDALIST trial on the use of luspatercept-aamt in patients with low-risk myelodysplastic syndromes.

The approval of imatinib almost 20 years ago heralded the arrival of the targeted therapy era in oncology and thrust the ABL1 kinase into the limelight.

The China National Medical Products Administration has accepted an application for gilteritinib for the treatment of adult patients with FLT3 mutation–positive acute myeloid leukemia.

We recently traveled to Chicago, Illinois for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from Rush University Medical Center faculty.

Although considerable progress has been made in treating diffuse large B-cell lymphoma since the advent of chemoimmunotherapy, approximately 33% of patients still develop relapsed/refractory disease, which is associated with considerable morbidity and mortality.

Paul M. Barr, MD, Wilmot Cancer Institute, University of Rochester, discusses the results of a phase I/II study evaluating the combination of umbralisib, ublituximab, and venetoclax (Venclexta) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

Aaron Goodman, MD, hematologist/oncologist and assistant professor of medicine at the University of California, San Diego, discusses the importance of the phase III ECHELON-2 data in peripheral T-cell lymphoma (PTCL).

The FDA has approved luspatercept for the treatment of anemia in patients with myelodysplastic syndromes.

Jerald P. Radich, MD, discusses the growing importance of MRD assessment in the treatment paradigm for patients with hematologic malignancies.

The European Commission has approved the rituximab biosimilar Ruxience for the treatment of patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris

The FDA has granted remestemcel-L a priority review designation for the treatment of children with steroid-refractory acute graft versus host disease.

Ivy P. Altomare, MD, discusses treatment options for patients with immune thrombocytopenia purpura.

Francine Foss, MD, discusses the challenges faced in cutaneous T-cell lymphoma.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of brentuximab vedotin (Adcetris) for use in combination with chemotherapy for the frontline treatment of adult patients with systemic anaplastic large cell lymphoma.

Results from the first FDA-approved in-human trial of CRISPR-edited T cells for cancer treatment suggest that such therapies can be used safely in patients, allaying some of the concerns about potential AEs and advancing progress toward the development of more effective cell-based immunotherapies.

Alvin H. Schmaier, MD, discusses managing thrombosis in patients with hematologic malignancies.